441 material Form 8-K filings that 376 companies we cover made with the SEC in June 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Five Below reported first-quarter fiscal 2025 net sales up 19.5% to $970.5 million and GAAP diluted EPS of $0.75, versus $0.57 a year earlier. The company raised its full-year 2025 sales guidance and the low end of its EPS guidance range, and it also said CFO Kristy Chipman will leave on June 6, 2025, with COO Kenneth Bull serving as interim CFO.
Q1 net sales rose 19.5% to $970.5 million; comparable sales rose 7.1%; adjusted diluted EPS was $0.86 versus $0.60
Full-year 2025 net sales guidance is $4.33 billion to $4.42 billion; full-year diluted EPS guidance is $4.04 to $4.51
CFO Kristy Chipman's employment ends June 6, 2025; COO Kenneth Bull will be interim CFO and Treasurer while a permanent replacement is sought
Argan reported results for the first quarter of fiscal 2026, ended April 30, 2025. Revenue rose 23% to $193.7 million, net income rose to $22.6 million from $7.9 million, and diluted EPS was $1.60 versus $0.58 a year earlier. Project backlog reached a record $1.9 billion, up from $1.36 billion at January 31, 2025, which the company said was driven by a full notice to proceed for the Sandow Lakes Power Station.
Revenue was $193.7 million, up $36.0 million or 23% from $157.7 million; gross margin was 19.0% versus 11.4%.
Net income was $22.6 million, or $1.60 per diluted share, compared with $7.9 million, or $0.58, a year earlier.
Project backlog was $1.856 billion at April 30, 2025, up from $1.361 billion at January 31, 2025.
Cash, cash equivalents and investments totaled $546.5 million, and the company reported no debt.
ANI Pharmaceuticals filed its investor presentation for the Jefferies Global Healthcare Conference, where CEO Nikhil Lalwani will speak on June 4, 2025. The slides restate 2025 guidance issued on May 9, 2025, which the company describes as its second guidance raise of the year, and they report first-quarter 2025 revenue and profit growth. The filing presents previously disclosed figures rather than new results, but the guidance increase is relevant to shareholders.
2025 net revenue guidance is $768 million to $793 million, up from $756 million to $776 million previously.
2025 adjusted non-GAAP EBITDA guidance is $195 million to $205 million, up from $190 million to $200 million; adjusted diluted EPS guidance is $6.27 to $6.62, up from $6.12 to $6.49.
First-quarter 2025 total revenue was $197 million, up 43% year over year, and adjusted non-GAAP EBITDA was $51 million, up 35%.
Q1 ILUVIEN and YUTIQ revenue of $16 million was temporarily affected by factors the company listed, including sales force turnover; the company said demand accelerated in Q2 2025.
THOR Industries reported fiscal third-quarter results for the period ended April 30, 2025, with net sales of $2.89 billion, up 3.3%, and diluted earnings per share of $2.53, up from $2.13. The company reaffirmed its revised fiscal 2025 guidance, and management said it expects the fourth quarter of fiscal 2025 and the first quarter of fiscal 2026 to be challenging. Nine-month results declined, with diluted EPS of $2.49 versus $3.26 a year earlier.
Third-quarter net sales of $2.89 billion, up 3.3%; gross profit margin of 15.3% versus 15.1%
Diluted EPS of $2.53 versus $2.13; net income attributable to THOR of $135.2 million versus $114.5 million
Fiscal 2025 guidance reaffirmed: net sales of $9.0 billion to $9.5 billion; diluted EPS of $3.30 to $4.00
Nine-month diluted EPS of $2.49 versus $3.26, down 23.6%; nine-month net sales down 6.0%
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.